At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
oxaliplatin, capecitabine, trastuzumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intra-hepatic Chemotherapy With Oxaliplatin Every Second Week in Combination With Systemic Capecitabine in Patient With Non-resectable Liver Metastases From Breast Cancer A Phase II Trial in Patients With Limited Extrahepatic Disease
In Brief
A Phase 2 clinical trial evaluating oxaliplatin, capecitabine, trastuzumab for Metastatic Breast Cancer and Liver Metastases. Completed, enrolled 38 participants across 1 site.
Detailed Summary
This is a phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic capecitabine and in patients with a HER2-positive tumour in combination with trastuzumab (Herceptin®) in patient with non-resectable liver metastases from breast cancer. Only patients with limited extrahepatic disease are included.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer, Liver Metastases
CountriesDenmark
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedJul 2011
Primary CompletionMay 2017
Study CompletionSep 2017
TodayJul 2026
First PostedJul 4, 2011
Enrollment StartApr 1, 2010
Primary CompletionMay 1, 2017
Study CompletionSep 1, 2017
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 15.0 years ago
Interventions
oxaliplatin, capecitabine, trastuzumabdrug
Oxaliplatin intrahepatic capecitabine and trastuzumab systemic